Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, PK, and PD of TLL018 in Healthy Subjects
NCT04243083Phase 1Completed
- Sponsor
- TLL Pharmaceutical, LLC
- Start
- Jan 2020
- Primary completion
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of girocitinib in rheumatoid arthritis (RA), autoimmune diseases and Inflammatory Disorders (3 arms), sponsored by TLL Pharmaceutical, LLC. Primary endpoints: Number of participants with treatment-emergent adverse events (AEs), serious adverse events (SAEs) and discontinuation due to AEs/SAEs, Change of blood pressure from baseline and 6 more. Started Jan 2020; status: completed.
02
Drugs
girocitinib
03
Conditions
rheumatoid arthritis (RA)autoimmune diseasesInflammatory Disorders
Beyond the preview
Go deeper on NCT04243083.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04243083.